Graft-versus-host disease (GvHD) is a severe complication that can occur after transplantation of human peripheral blood mononuclear cells (PBMCs) into mice, leading to serious illness and affecting the observation of drug efficacy. Gempharmatech has developed the NCG-MHC-dKO mouse model, which effectively alleviates GvHD caused by human PBMC transplantation in mice while maintaining the normal half-life of IgG antibodies, making it suitable for CD3 T cell function and antibody drug research. The features of the NCG-MHC-dKO mouse model are as follows:
Impact on alleviating GvHD:
Compared to NCG mice, the NCG-MHC-dKO mice exhibit a lower incidence and severity of GvHD after transplantation of allogeneic human PBMCs.
Impact on IgG half-life:
It is worth noting that the NCG-MHC-dKO mouse model maintains the normal half-life of IgG antibodies.
CD3 T cell function and antibody drug research:
By transplanting human PBMCs, the NCG-MHC-dKO mouse model provides a unique opportunity to study the activation, proliferation, and function of different CD3 T cell subsets, further exploring their role in GvHD development and providing important information for the development of new immune therapy strategies. In addition, the NCG-MHC-dKO mouse model can also be used to evaluate the efficacy and safety of CD3 T cell function antibody drugs, providing strong support for the research and development of anti-tumor immunotherapy.
Visit our website to learn more about our Next-Gen NCG Models. https://en.gempharmatech.com/product/models_list100139_170077.html
